Total Price: $0.00
Contact Information
Recombinant Human PD-L1/B7-H1/CD274 protein (His tag)
SKU: PDEH100234-100
To better serve you, we would like to discuss your specific requirement.
Please Contact Us for a quote.
Recombinant Human PD-L1/B7-H1/CD274 protein (His tag)
| SKU # | PDEH100234 |
| Expression Host | E. coli |
Description
| Synonyms | Programmed Cell Death 1 Ligand 1;PD-L1;PDCD1 ligand 1;Programmed death ligand 1;B7 homolog 1;B7-H1;CD274;B7H1;PDCD1L1;PDCD1LG1;PDL1 |
| Species | Human |
| Expression_host | E.coli |
| Sequence | Phe19-Thr 239 |
| Accession | Q9NZQ7 |
| Mol_Mass | 24.1 kDa |
| AP_Mol_Mass | 31 kDa |
| Tag | N-His |
| Bio_Activity | Not validated for activity |
Properties
| Purity | > 95 % as determined by reducing SDS-PAGE. |
| Endotoxin level | Please contact us for more information. |
| Storage | Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months. |
| Shipping | This product is provided as lyophilized powder which is shipped with ice packs. |
| Formulation | Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Please refer to the specific buffer information in the printed manual. |
| Reconstitution | It is recommended that sterile water be added to the vial to prepare a stock solution of 0.5 mg/mL. Concentration is measured by UV-Vis |
Background
CD274; also known as B7-H1 or programmed death ligand 1 (PD-L1); is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. Programmed death-1 ligand-1 (PD-L1; CD274; B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. By binding to PD1 on activated T-cells and B-cells; PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly; it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.